Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)

Journal of Bone and Mineral Metabolism

Volumn 23, Issue 2, 2005, Pages 97-104

  Nishizawa, Yoshiki ^a   Nakamura, Toshitaka ^b   Ohta, Hiroaki ^c   Kushida, Kazuhiro ^d   Gorai, Itsuo ^e   Shiraki, Masataka ^f   Fukunaga, Masao ^g   Hosoi, Takayuki ^h   Miki, Takami ^a   Chaki, Osamu ⁱ   Ichimura, Schoichi ^j   Nakatsuka, Kiyoshi ^k   Miura, Masakazu ^l  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e International University of Health and Welfare   (Japan)

^f RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^g KAWASAKI MEDICAL SCHOOL   (Japan)

^h Tokyo Metropolitan Institute of Gerontology   (Japan)

ⁱ YOKOHAMA CITY UNIVERSITY   (Japan)

^j KYORIN UNIVERSITY   (Japan)

^k ELI LILLY AND COMPANY   (United States)

^l LSI MEDIENCE CORPORATION   (Japan)

more..

Author keywords

Guideline; Markers of bone turnover; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; ESTROGEN; FARNOQUINONE; HORMONE; IPRIFLAVONE; OSTEOCALCIN; PEPTIDE DERIVATIVE; PROCOLLAGEN; PROCOLLAGEN TYPE I AMINOPROPEPTIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

BONE TURNOVER; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE SUBSTITUTION; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; COLLAGEN TYPE I; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; REFERENCE VALUES; RISK;

EID: 20944436377     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-004-0547-6     Document Type: Review

References (31)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) JAMA 285:785-795
2. Weinstein RS (2000) True strength. J Bone Miner Res 15:621-625
3. Chesnut CH III, Rosen CJ for the Bone Quality Discussion Group (2001) Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163-2172
4. Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16-37
5. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Iga T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
6. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement of spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:282-289
7. Heaney RP (2003) Is the paradigm shifting? Bone 33:457-465
8. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women; EPIDOS prospective study. J Bone Mineral Res 11:1531-1538
9. Garnero P, Sornay-Rendu E, Claustrar B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fracture in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526-1536
10. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures; a prospective study. Osteoporos Int 11:76-82
11. Shiraki M, Kushida K, Fukunaga M for the Alendronate Phase III Osteoporosis Research Group (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporosis Int 10:183-192
12. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamurà T, Itabashi A, Sarkar S, Harper K (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14:793-800
13. Nishizawa Y (2003) A Survey of diagnosis and treatment in Japan (in Japanese). Osteoporosis Jpn 11:631-643
14. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB (1999) Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 2:323-342
15. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) A position paper on the use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 10 (Suppl 6):S2-S17
16. Looker A, Bauer DC, Chesnut C III, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH (2000) Clinical use of biochemical markers of bone remodeling: current status, future directions. Osteoporos Int 11:467-480
17. Committee of Use of Biochemical Markers of Bone Turnover in Osteoporosis, Japan Osteoporosis Society (2001) Guidelines on the use of biochemical markers of bone turnover in osteoporosis (in Japanese). Osteoporosis Jpn 9:255-271
18. Committee of Use of Biochemical Markers of Bone Turnover in Osteoporosis, Japan Osteoporosis Society (2002) Guidelines on the use of biochemical markers of bone turnover in osteoporosis (in Japanese). Osteoporosis Jpn 10:251-261
19. Bjarnason NH, Sarker S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and 12 month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930
20. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
21. Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone
22. Delmas PD, Vrijens B, Roux C, et al. (2003) A reinforcement message based on bone turnover marker response influences: long-term persistence with risedronate in osteoporosis: IMPACT study. J Bone Miner Res 18 (Suppl 2):S374
23. Yoshimura N, Nakatsuka K, Saito S, et al. (2002) Measurements of serum type I procollagen N propeptide (PINP) in normal Japanese population: establishment of age and sex specific reference ranges (in Japanese). Osteoporosis Jpn 10:539-544
24. Saito S, Nakatsuka K, Masaki H, et al. (2003) Consistency of cut off levels of various metabolic bone markers determined by risks of bone loss of postmenopausal women (in Japanese). Osteoporosis Jpn 11:201-204
25. Nakatsuka K, Nishizawa Y (2001) Metabolic bone markers in severe osteoporosis (in Japanese). Clinical Calcium 11:1572-1576
26. Nakatsuka K, Miura M, Miki T, et al. (2001) Use of serum metabolic markers in assessing of efficacy of hormone replacement therapy in postmenopausal osteoporosis (in Japanese). Jpn J Bone Miner Res 19:63
27. Miki T, Nakatsuka K, Naka H, Masaki H, Saito S, Tomiyoshi Y, Inaba M, Nishizawa Y (2004) Measurements of serum type I procollagen N propeptide (PINP) in postmenopausal osteoporosis treated with intermittent cyclical etidronate (in Japanese). Osteoporosis Jpn 12:219-224
28. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431-1438
29. Eastell R, Brainbridge PR (2003) Bone turnover markers: their place in the investigation of osteoporosis. In: Orwoll ES, Bliziotes M (eds) Osteoporosis: Pathophysiology and Clinical Management. Humana, Totowa, NJ, pp 185-197
30. Nakatsuka K, Komo K, Masaki H, et al. (2002) Intralaboratory variation of metabolic bone markers in Japan: results from a first survey (in Japanese). Clinical Endocrinology 50:419-425
31. Ichimura S (2004) Intralaboratory variation of metabolic bone markers in Japan: results from a second survey. Osteoporosis Jpn 12:214-218